Literature DB >> 16133363

Quantification of clonal hematopoiesis in polycythemia vera.

Udo Siebolts1, Murat Ates, Rüdiger Spitz, Jürgen Thiele, Claudia Wickenhauser.   

Abstract

Polycythemia vera (PV) is believed to represent a clonal trilineage myeloaccumulative hematopoietic disorder. This study was undertaken to estimate for the first time the proportion not only of the neoplastic clone but also of clonal and residual nonneoplastic CD34(+) progenitor cells. Chromosomal abnormalities, including trisomy 8 or 9, are phenomena associated in about 20% of PV patients. Therefore, we screened peripheral blood (PB) mononuclear cells of PV patients in the chronic phase of the disease and looked for chromosomal abnormalities performing comparative genomic hybridization. Two of the ten patients revealed cytogenetic changes, including trisomy 8 or 9. To quantify the proportion of cytogenetic abnormal cells in these patients, we applied fluorescence in situ hybridization (FISH) technique on immunomagnetically enriched cell fractions. Ninety percent of the mononuclear cells and up to 79% of PB-derived CD34(+) progenitor cells presented three signals for chromosome 8 or 9. The diagnostic value of FISH to detect trisomies in trephine biopsies was then tested in all patients under study. Although the probability to detect FISH signals in a certain section plane is reduced, constantly 10-15% of the cells revealed three signals. Concerning the CD34(+) progenitor cell pool, a distinct nonclonal population exists in these patients. Our data underline the stem cell character of PV and additionally quantify the proportion of clonal CD34(+) progenitor cells for the first time. The finding of a distinct, not aberrant, CD34(+) progenitor cell population in chronic phase PV may offer perspectives in treatment of the disease. Finally, FISH analysis of bone marrow biopsies can be helpful to consolidate diagnosis of early PV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133363     DOI: 10.1007/s00428-005-0047-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization.

Authors:  N B Westwood; A M Gruszka-Westwood; C E Pearson; C F Delord; A R Green; B J Huntly; A Lakhani; M F McMullin; T C Pearson
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

Review 2.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

3.  Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia.

Authors:  Lourdes Florensa; Carles Besses; Lurdes Zamora; Beatriz Bellosillo; Blanca Espinet; Sergi Serrano; Soledad Woessner; Francesc Solé
Journal:  Blood       Date:  2004-03-15       Impact factor: 22.113

4.  Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization.

Authors:  N B Westwood; A M Gruszka-Westwood; S Atkinson; T C Pearson
Journal:  Haematologica       Date:  2001-05       Impact factor: 9.941

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity.

Authors:  S Knuutila; G Armengol; A M Björkqvist; W el-Rifai; M L Larramendy; O Monni; J Szymanska
Journal:  Cancer Genet Cytogenet       Date:  1998-01-01

8.  Cryptic translocations involving chromosome 20 in polycythemia vera.

Authors:  Maryvonne Busson; Serge Romana; Florence Nguyen Khac; Olivier Bernard; Roland Berger
Journal:  Ann Genet       Date:  2004 Oct-Dec

9.  Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.

Authors:  Robert Kralovics; Andreas S Buser; Soon-Siong Teo; Jorn Coers; Andre Tichelli; Anthonie P C van der Maas; Radek C Skoda
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

10.  Structural, antigenetic and transcriptional characteristics in peripheral blood CD34+ progenitor cells from polycythemia vera patients: evidence for delayed determination.

Authors:  Claudia Wickenhauser; Fernando Pérez; Udo Siebolts; Johann Lorenzen; Eva Varus; Semra Frimpong; Jürgen Thiele
Journal:  Int J Oncol       Date:  2003-08       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.